ovid.com
Cure8 news brief
Why This Matters
An uncommon oropharyngeal mass due to Crohn’s disease can be diagnostically challenging and may not respond to corticosteroids or anti-TNF therapy. For some patients, switching to a different mechanism (here, a JAK inhibitor) may lead to clinical and endoscopic improvement.
Who Should Pay Attention
Adults with Crohn’s disease (especially with oral/oropharyngeal symptoms), clinicians treating refractory IBD, and patients on anti-TNF biologics.
Study Snapshot
Story typeResearch paper
Evidence typeCase report
Source depthFull source text
What To Know
This is a single case report of a 74-year-old man with longstanding colonic and perianal Crohn’s disease on infliximab who developed a mass-like oropharyngeal lesion. Biopsies showed non-necrotizing granulomas and infectious and malignant causes were excluded.
The lesion did not respond to corticosteroids or supratherapeutic infliximab levels but improved after switching to upadacitinib, with endoscopic and clinical resolution and later maintenance on upadacitinib.
The patient required a temporary gastrostomy tube for nutrition while swallowing improved on upadacitinib; later he required escalation to dual therapy with risankizumab for worsening luminal and perianal disease.
This report highlights an unusual extraintestinal manifestation of Crohn’s disease that was refractory to anti-TNF therapy and responsive to a JAK inhibitor in this single patient. It illustrates diagnostic challenges (broad differential, need for biopsy and multidisciplinary review) and that treatment may need to be individualized in refractory cases.
Keep In Mind
Single-patient case report—useful as a signal but not proof of general effectiveness. The authors report thorough exclusion of other causes and document objective improvement after therapy change.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationovid.com
Indexed viaGoogle News
Source typeWeb article
PublishedAug 18, 2026, 1:28 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Small Intestinal Extranodal Marginal Zone... : ACG Case Reports Journal - Ovid
Some cancers of the small intestine can look like Crohn’s disease. If symptoms don’t fit typical IBD patterns or don’t respond as expected to therapy, re-evaluation may be needed to avoid delays in diagnosis and...
Risk factors for long-term surgical recurrence following ileocecal resection for Crohn’s disease
The study highlights factors linked to needing another operation after ileocecal resection for Crohn’s disease and suggests postoperative biologic therapy may lower long-term reoperation risk. That directly affects...
SURGICAL APPROACH, BIOLOGICAL THERAPIES, AND INFLAMMATORY MECHANISMS ASSOCIATED WITH ULCERATIVE COLITIS AND CROHN'S DISEASE
The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and...